search
Back to results

Biological Skin Graft With Keratinocyte-stem Cell Co-cultre for Burn Patients

Primary Purpose

Burn Degree Second, Burn Degree Third

Status
Recruiting
Phase
Early Phase 1
Locations
Indonesia
Study Type
Interventional
Intervention
Split-thickness skin graft
Artificial skin graft
Artificial skin graft co-culture
Sponsored by
Indonesia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Burn Degree Second focused on measuring artificial skin graft, keratinocyte, amnion epithelial stem cells, burn

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Aged 18 - 55 Area of burn <50% Acute phase burn (<120 hrs) Have not undergo any surgery for burn treatment Exclusion Criteria: Immunocompromised Have comorbidities

Sites / Locations

  • RSUPN Cipto MangunkusumoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Sham Comparator

Experimental

Experimental

Arm Label

STSG (Split-Thickness Skin Graft)

Amnion Bilayer Only

Amnion Bilayer seeded with co-culture

Arm Description

Patients treated with the standard treatment; autologous skin graft

Patients treated with artificial graft only

Patients treated with artificial graft seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells

Outcomes

Primary Outcome Measures

Burn thickness
Thickness of burn evaluation using Rule of 9
Burn thickness
Thickness of burn evaluation using Rule of 9
Burn thickness
Thickness of burn evaluation using Rule of 9
Burn thermography
Thermography evaluation using FLIRONE
Burn thermography
Thermography evaluation using FLIRONE
Burn thermography
Thermography evaluation using FLIRONE
Systemic clinical evaluation
Mean arterial pressure measurement
Systemic clinical evaluation
Mean arterial pressure measurement
Systemic clinical evaluation
Mean arterial pressure measurement
Systemic clinical evaluation
lactate measurement
Systemic clinical evaluation
lactate measurement
Systemic clinical evaluation
lactate measurement
Systemic clinical evaluation
procalcitonin measurement
Systemic clinical evaluation
procalcitonin measurement
Systemic clinical evaluation
procalcitonin measurement
Systemic clinical evaluation
urine excretion rate measurement
Systemic clinical evaluation
urine excretion rate measurement
Systemic clinical evaluation
urine excretion rate measurement
Histoarchitecture evaluation
Haematoxylin & Eosin staining
Histoarchitecture evaluation
Haematoxylin & Eosin staining
Histoarchitecture evaluation
Movat's Pentachrome staining
Histoarchitecture evaluation
Movat's Pentachrome staining
Immunohistochemistry
collagen-1 labelling
Immunohistochemistry
collagen-1 labelling
Immunohistochemistry
collagen-3 labelling
Immunohistochemistry
collagen-3 labelling
Immunohistochemistry
von Willebrand labelling
Immunohistochemistry
von Willebrand labelling
Immunohistochemistry
alpha-Smooth Muscle Actin labelling
Immunohistochemistry
alpha-Smooth Muscle Actin labelling
Wound healing relative gene expression
TGFB1
Wound healing relative gene expression
TGFB1
Wound healing relative gene expression
TGFB3
Wound healing relative gene expression
TGFB3
Wound healing relative gene expression
Wnt4
Wound healing relative gene expression
Wnt4
Wound healing relative gene expression
CTNNB1
Wound healing relative gene expression
CTNNB1
Wound healing relative gene expression
MMP2
Wound healing relative gene expression
MMP2
Wound healing relative gene expression
MMP9
Wound healing relative gene expression
MMP9

Secondary Outcome Measures

Full Information

First Posted
November 29, 2022
Last Updated
December 8, 2022
Sponsor
Indonesia University
search

1. Study Identification

Unique Protocol Identification Number
NCT05652816
Brief Title
Biological Skin Graft With Keratinocyte-stem Cell Co-cultre for Burn Patients
Official Title
Substitute Graft for Burns Using Biological Graft Seeded With Autologous Keratinocyte Co-cultured With Stem Cells
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 6, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indonesia University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to test whether artificial skin graft can substitute autologous skin graft in current burn treatment. The main question it aims to answer is: • Can artificial skin graft result in better wound healing compared to the current burn treatment; autologous skin graft? You will: Undergo debridement surgery Receive artificial skin graft as an alternative to autologous skin graft Undergo biopsy procedure of burn area If there is a comparison group: Researchers will compare autologous skin graft group to see the wound healing process
Detailed Description
Burn caused by working accidents occurs mostly in the male population of productive age (68.68%). Up to this date, the only treatment for grade 2B-3 burns patients in Indonesia is skin transplantation taken from their own body (autologous skin graft). This treatment has several drawbacks in which repeated surgery is sometimes necessary, the source of skin in patients with wide area of burn is limited, and patients that are in the elder age and have comorbidities have high mortality risk. In order to find an alternative for autologous skin graft therapy, a combination of tissue engineering and stem cell therapy is used to invent an artificial skin graft. The present study attempts to evaluate the efficacy of artificial skin graft seeded with autologous keratinocyte and stem cells towards wound healing in burn patients. The artificial graft used in this study is amnion bilayer; a graft that was decellularized to remove donor's cells and then layered to form into 3-D. To evaluate the efficacy, biopsies are taken from the burn area of patients to evaluate the histoarchitecture of patients' tissue by histological staining (H&E and Movat's pentachrome, IHC collagen I, collagen III, vWF, and alpha-SMA) and measure the relative gene expression by qPCR. For clinical data, burn area calculation using Rule of 9 method and thermography measurement using FLIRONE. Furthermore, systemic evaluation of patients are done by monitoring the procalcitonin, lactate, mean arterial pressure, gradation of wound, and sensory of burn area. The evaluation and measurement mentioned above are then compared to patients treated with the current available therapy; autologous skin graft. The artificial skin graft is hoped to result in equal, if not better, wound healing in burn patients compared to autologous skin graft. The investigators hope that artificial skin graft can be an option, other than autologous skin graft, in treating burn patients in the future.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Burn Degree Second, Burn Degree Third
Keywords
artificial skin graft, keratinocyte, amnion epithelial stem cells, burn

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
STSG (Split-Thickness Skin Graft)
Arm Type
Sham Comparator
Arm Description
Patients treated with the standard treatment; autologous skin graft
Arm Title
Amnion Bilayer Only
Arm Type
Experimental
Arm Description
Patients treated with artificial graft only
Arm Title
Amnion Bilayer seeded with co-culture
Arm Type
Experimental
Arm Description
Patients treated with artificial graft seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
Intervention Type
Procedure
Intervention Name(s)
Split-thickness skin graft
Intervention Description
Transplantation of autologous skin to burn area
Intervention Type
Biological
Intervention Name(s)
Artificial skin graft
Intervention Description
Decellularized amnion membrane formed into 3-D matrix
Intervention Type
Biological
Intervention Name(s)
Artificial skin graft co-culture
Intervention Description
Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
Primary Outcome Measure Information:
Title
Burn thickness
Description
Thickness of burn evaluation using Rule of 9
Time Frame
Day of surgery
Title
Burn thickness
Description
Thickness of burn evaluation using Rule of 9
Time Frame
Day 7 after surgery
Title
Burn thickness
Description
Thickness of burn evaluation using Rule of 9
Time Frame
Day 14 after surgery
Title
Burn thermography
Description
Thermography evaluation using FLIRONE
Time Frame
Day of surgery
Title
Burn thermography
Description
Thermography evaluation using FLIRONE
Time Frame
Day 7 after surgery
Title
Burn thermography
Description
Thermography evaluation using FLIRONE
Time Frame
Day 14 after surgery
Title
Systemic clinical evaluation
Description
Mean arterial pressure measurement
Time Frame
Day of surgery
Title
Systemic clinical evaluation
Description
Mean arterial pressure measurement
Time Frame
Day 7 after surgery
Title
Systemic clinical evaluation
Description
Mean arterial pressure measurement
Time Frame
Day 14 after surgery
Title
Systemic clinical evaluation
Description
lactate measurement
Time Frame
Day of surgery
Title
Systemic clinical evaluation
Description
lactate measurement
Time Frame
Day 7 after surgery
Title
Systemic clinical evaluation
Description
lactate measurement
Time Frame
Day 14 after surgery
Title
Systemic clinical evaluation
Description
procalcitonin measurement
Time Frame
Day of surgery
Title
Systemic clinical evaluation
Description
procalcitonin measurement
Time Frame
Day 7 after surgery
Title
Systemic clinical evaluation
Description
procalcitonin measurement
Time Frame
Day 14 after surgery
Title
Systemic clinical evaluation
Description
urine excretion rate measurement
Time Frame
Day of surgery
Title
Systemic clinical evaluation
Description
urine excretion rate measurement
Time Frame
Day 7 after surgery
Title
Systemic clinical evaluation
Description
urine excretion rate measurement
Time Frame
Day 14 after surgery
Title
Histoarchitecture evaluation
Description
Haematoxylin & Eosin staining
Time Frame
Day of surgery
Title
Histoarchitecture evaluation
Description
Haematoxylin & Eosin staining
Time Frame
Day 14 after surgery
Title
Histoarchitecture evaluation
Description
Movat's Pentachrome staining
Time Frame
Day of surgery
Title
Histoarchitecture evaluation
Description
Movat's Pentachrome staining
Time Frame
Day 14 after surgery
Title
Immunohistochemistry
Description
collagen-1 labelling
Time Frame
Day of surgery
Title
Immunohistochemistry
Description
collagen-1 labelling
Time Frame
Day 14 after surgery
Title
Immunohistochemistry
Description
collagen-3 labelling
Time Frame
Day of surgery
Title
Immunohistochemistry
Description
collagen-3 labelling
Time Frame
Day 14 after surgery
Title
Immunohistochemistry
Description
von Willebrand labelling
Time Frame
Day of surgery
Title
Immunohistochemistry
Description
von Willebrand labelling
Time Frame
Day 14 after surgery
Title
Immunohistochemistry
Description
alpha-Smooth Muscle Actin labelling
Time Frame
Day of surgery
Title
Immunohistochemistry
Description
alpha-Smooth Muscle Actin labelling
Time Frame
Day 14 after surgery
Title
Wound healing relative gene expression
Description
TGFB1
Time Frame
Day of surgery
Title
Wound healing relative gene expression
Description
TGFB1
Time Frame
Day 14 after surgery
Title
Wound healing relative gene expression
Description
TGFB3
Time Frame
Day of surgery
Title
Wound healing relative gene expression
Description
TGFB3
Time Frame
Day 14 after surgery
Title
Wound healing relative gene expression
Description
Wnt4
Time Frame
Day of surgery
Title
Wound healing relative gene expression
Description
Wnt4
Time Frame
Day 14 after surgery
Title
Wound healing relative gene expression
Description
CTNNB1
Time Frame
Day of surgery
Title
Wound healing relative gene expression
Description
CTNNB1
Time Frame
Day 14 after surgery
Title
Wound healing relative gene expression
Description
MMP2
Time Frame
Day of surgery
Title
Wound healing relative gene expression
Description
MMP2
Time Frame
Day 14 after surgery
Title
Wound healing relative gene expression
Description
MMP9
Time Frame
Day of surgery
Title
Wound healing relative gene expression
Description
MMP9
Time Frame
Day 14 after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 - 55 Area of burn <50% Acute phase burn (<120 hrs) Have not undergo any surgery for burn treatment Exclusion Criteria: Immunocompromised Have comorbidities
Facility Information:
Facility Name
RSUPN Cipto Mangunkusumo
City
Jakarta Pusat
State/Province
DKI Jakarta
ZIP/Postal Code
10430
Country
Indonesia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aditya Wardhana, MD
Phone
+6287880021350
Email
aditya_wrdn@yahoo.com
First Name & Middle Initial & Last Name & Degree
Normalina Sandora, PhD
Phone
+6281298963425
Email
normalina.sandora@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Biological Skin Graft With Keratinocyte-stem Cell Co-cultre for Burn Patients

We'll reach out to this number within 24 hrs